last
decad
manag
patient
hemophilia
wit
dramat
improv
larg
avail
safe
plasmaderiv
recombin
product
replac
therapi
anoth
import
step
forward
relat
larger
larger
implement
primari
prophylaxi
children
secondari
prophylaxi
adult
chronic
synov
recurr
bleed
current
main
problem
patient
hemophilia
onset
antibodi
inactiv
infus
clot
factor
inhibitor
even
though
advent
immun
toler
regimen
capabl
erad
inhibitor
avail
product
bypass
intrins
coagul
defect
improv
manag
patient
cure
hemophilia
gene
transfer
attempt
rel
far
implement
larg
scale
last
two
decad
second
millennium
wit
dramat
improv
manag
patient
inherit
factor
viii
fviii
ix
fix
defici
hemophilia
also
excel
weapon
treatment
von
willebrand
diseas
inherit
bleed
disord
due
defici
multimer
glycoprotein
von
willebrand
factor
current
situat
much
less
satisfactori
recess
inherit
coagul
disord
still
mainli
treat
freshfrozen
plasma
cryoprecipit
latter
employ
afibrinogenemia
factor
xiii
defici
plasma
factor
current
high
degre
safeti
plasmaderiv
fviii
fix
concentr
stem
adopt
method
meant
detect
presenc
virus
sourc
plasma
inactiv
may
escap
screen
virucid
method
pasteur
dryheat
high
temperatur
solventdeterg
nanofiltr
current
perceiv
threat
abnorm
prion
caus
new
variant
creutzfeldtjakob
diseas
might
transmit
blood
product
although
plasma
fraction
process
seem
abl
remov
larg
amount
prion
emerg
infecti
agent
coronaviru
caus
sar
west
nile
viru
caus
avian
influenza
consid
impend
risk
transfus
patient
hemophilia
viremia
transient
current
virucid
method
abl
inactiv
sinc
earli
case
transmiss
viral
infect
hepat
hiv
document
patient
hemophilia
recombin
factor
avail
product
treatment
hemophilia
increas
safeti
replac
therapi
efficaci
safeti
clearli
shown
prospect
studi
carri
earli
previous
treat
untreat
patient
post
licensur
experi
first
gener
product
come
contact
humanand
animalderiv
protein
manufactur
formul
concern
use
humanand
animalderiv
protein
led
elimin
manufactur
process
recombin
fviii
fix
manufactur
without
contact
protein
stabil
human
albumin
final
formul
target
improv
recombin
fviii
increas
stabil
avail
enhanc
express
specif
activ
molecul
render
less
immunogen
less
neoantigen
remov
replac
domain
trigger
frequent
inhibitor
develop
slow
fviii
plasma
clearanc
order
increas
time
interv
dose
set
prophylaxi
latter
strategi
seem
moment
advanc
toward
clinic
use
hemophilia
b
patient
plan
produc
larg
amount
protein
milk
transgen
pig
call
bioreactor
patient
inhibitor
treatment
bypass
defect
fviii
ix
intrins
coagul
dramat
improv
manag
patient
previous
high
rate
musculoskelet
abnorm
even
death
due
uncontrol
bleed
step
forward
avail
plasmaderiv
bypass
fraction
contain
activ
nonactiv
form
fii
fix
fx
control
amount
recent
recombin
prepar
activ
factor
vii
even
though
success
rate
prepar
control
bleed
somewhat
lower
success
rate
obtain
recombin
fviii
fix
hemophiliac
without
inhibitor
clinic
situat
previous
poorli
handl
includ
elect
surgic
procedur
success
carri
use
product
also
possibl
clear
inhibitor
protocol
immun
toler
involv
continu
administr
larg
dose
fviii
inhibitor
longer
detect
patient
respond
fviii
gene
transfer
least
trial
gene
transfer
hemophilia
b
start
last
year
earli
result
encourag
measur
level
fviii
fix
obtain
patient
enrol
phase
iii
clinic
trial
none
patient
develop
inhibitor
factor
produc
transfect
gene
limit
earli
studi
short
limit
express
transgen
plasma
factor
level
low
transient
detect
truli
improv
clinic
pictur
problem
host
immunolog
reaction
vector
transient
presenc
transgen
semin
fluid
recipi
observ
insert
mutagenesi
patient
scid
treat
retrovir
vector
must
born
mind
current
avail
treatment
hemophilia
safe
efficaci
monogen
diseas
hemophilia
perhap
prefer
earli
model
gene
transfer
muscular
dystrophi
cystic
fibrosi
scid
conclus
treatment
hemophilia
dramat
improv
sinc
concentr
fviii
fix
made
possibl
home
treatment
regular
prophylaxi
unfortun
dramat
progress
treatment
led
increas
life
expect
qualiti
life
patient
dramat
halt
epidem
hiv
infect
hepat
problem
tackl
effici
rapidli
progress
took
avail
safe
concentr
recombin
plasma
deriv
begin
third
millennium
wit
advent
gene
therapi
howev
yet
led
cure
hemophilia
patient
eagerli
await
current
fviii
inhibitor
remain
import
unresolv
problem
even
though
life
expect
qualiti
life
patient
improv
unresolv
issu
whether
product
replac
therapi
contain
fviii
typic
recombin
product
liabl
trigger
onset
inhibitor
previous
untreat
hemophiliac
product
addit
fviii
contain
also
von
willebrand
factor
typic
plasma
deriv
product
author
receiv
honoraria
speaker
sever
meet
organ
manufactur
product
employ
treatment
hemophilia
specif
sourc
fund
content
manuscript
neither
prepar
manuscript
correspond
pm
mannucci
md
via
pace
milan
itali
tel
fax
email
address
pmmannucci
liberoit
